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Aims: Myocardial infarction networks have been shown to improve guideline adherent therapy and outcomes in
patients presenting with acute ST-elevation myocardial infarction (STEMI). Our objective was to assess the short
term cost effectiveness of a network structure.
Methods and results: Outcome data and reimbursement data for the index hospital stay were gathered in
consecutive patients with acute STEMI (n = 536) admitted to any of the hospitals in a 350.000 inhabitant rural
network area during the years 2002 (n = 185), 2005 (n = 163) and 2008 (n = 188). Network structure was established
between 2002 and 2005 aiming for identical treatment of all acute STEMI patients during 24 h/7d a week with
primary angioplasty. Patient baseline characteristics in the different years were quite comparable. From 2002 to
2005 regional hospital mortality in STEMI patients decreased from 16% to 9%. Lower mortality under network
conditions was confirmed in 2008. Reimbursement data of different years were standardized to exclude effects not
induced by the network. The mean initial costs per saved live during the index stay were €7727 with a 95%-
confidence interval of €-3.500 to €36.700 (referenced to the German reimbursement in 2005).
Conclusion: The short term cost effectiveness of a myocardial infarction network organisation is within well
accepted boundaries under conditions of the German reimbursement system.
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After a steep increase in infarction mortality in the
nineteen-fifties and nineteen-sixties myocardial infarction
became the most frequent cause of death world wide.
Since the nineteen-nineties infarction mortality is on the
decline again. This was induced by behavioural changes
with respect to modifiable risk factors and a better acute
and chronic therapy for patients presenting with acute
myocardial infarction. A cornerstone of the acute infarc-
tion therapy is timely reperfusion of the infarct-related
artery either performed pharmacologically or mechanic-
ally. Timely reperfusion is especially demanded for ST-
elevation myocardial infarction (STEMI) which is an
entity of myocardial infarctions that can be readily identi-
fied by well-defined criteria in the rest electrocardiogram* Correspondence: rbirkemeyer@t-online.de
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reproduction in any medium, provided the orig(ECG) and clinical symptoms. There are only a few condi-
tions which mimic the ECG changes and symptoms of a
STEMI. These so called masquerading STEMI’s usually
represent less than 5% of the initially diagnosed STEMI
patients [1].
Primary percutaneous coronary intervention (PCI) is the
mechanical reperfusion method in myocardial infarction. It
is superior to pharmacological reperfusion with fibrinolysis
in patients presenting with acute ST-elevation myocardial
infarction (STEMI) when it can be performed expeditiously
by an experienced team in a hospital with an established
interventional cardiology programme (24 h/7 days) and the
PCI related time delay compared to fibrinolysis is no lon-
ger than 90–120 minutes [2-8]. Lowest mortality rates
among patients undergoing primary PCI are observed in
centres with a high volume of PCI procedures [9,10].
Therefore optimal treatment of STEMI should be based on
the implementation of a network between hospitals with
various levels of technology, connected by an efficient am-
bulance or helicopter service [2,11].s is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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recently been published which show that implementation
of myocardial infarction network structures in fact pro-
motes guideline adherent therapy and reduces mortality
[12-18]. Patients at high risk seem to profit most [12,18].
Whereas some data exist on the cost effectiveness of
primary PCI compared to fibrinolysis [19-21] such data
lack for the implementation of an emergency medical
services-based routine transfer for primary PCI com-
pared to standard care with concomitant use of transfer
PCI and fibrinolysis at the discretion of the local hos-
pital. Emergency medical services-based routine transfer
was identified as the most cost-effective approach to
promote access to primary PCI in a simulation of differ-
ent strategies in the U.S. American setting [22].
Routine transfer PCI however might have an underestimated
impact on short term health care expenditures due to
better access of critically ill STEMI patients to complex
intensive care treatment including mechanical circula-
tory support.
Therefore we collected and analyzed reimbursement data
in a regional all comer registry in the last year before and
the first year after network implementation. Consistency of
the network induced changes was checked by an additional
data collection three years after.
Methods
Organization of the regional network
The network serves a rural population of approximately
350,000 inhabitants. The diameter of the network region
is up to 70 km. There are six public regional hospitals, five
of them without cathlabs and one with a high-volume
interventional facility and a 24 h/7d primary PCI service.
Network structures include 12-lead ECG in the ambu-
lance, ECG telemetry to the intensive care unit of the in-
vasive facility, a structured phone call between emergency
medical services (EMS) and the intensive care physician
on call and preparation of the cathlab before patient ar-
rival. STEMI patients are intended to be directly admitted
to the cathlab, irrespective of the presence of cardiogenic
shock or resuscitation.
The uniform, regional primary PCI protocol aims for
identical treatment of all acute STEMI patients during
24 h/7d a week in one interventional centre. In a popula-
tion based analysis it was already shown that approxi-
mately 90% of patients with acute STEMI being admitted
to any of the hospitals in the network area received pri-
mary PCI [18]. Nearly all patients who were not scheduled
for primary PCI were excluded from any revascularisation
attempt due to co-morbidities.
Study population and follow up
All consecutive patients with the clinical diagnosis of
acute ST-elevation myocardial infarction (symptomduration <12 hours) admitted to any of the network area
hospitals during the years 2002 (n = 185), 2005 (n = 163)
and 2008 (n = 188) were included in this registry irre-
spective of their treatment. The network was established
in between 2002 and 2005.
All patients in the invasive facility were prospectively
documented in a dedicated database. Completeness was
checked by comparison with the compulsory ICD-10 en-
coding of the clinical diagnoses in the hospital discharge
dataset (code I21.X with exclusion of non ST-elevation
myocardial infarctions). All patients treated exclusively
in the non cathlab hospitals were retrospectively identified
by their ICD-10 encoding as described above. Clinical files
of those patients were subsequently checked by one cli-
nician. Reimbursement data on the index stay for each single
patient was obtained from hospital databases. Reimburse-
ment for cardiac surgery was included in the analysis if pa-
tients were directly transferred for cardiac surgery.
Follow up was obtained by telephone interviews and
questionnaires at 6 months with complete information
on mortality gathered from state registries. The registry
was approved by the local ethics committee. All patients
were asked for their informed consent for the extension
of the institutional routine follow-up.
Assessment of quality of life after primary PCI under
network conditions
From January 2005 to mid 2007 about 500 hundred
STEMI patients were scheduled for primary PCI under
network conditions. These consecutive patients received
the German version of the MacNew heart disease health-
related quality of life questionnaire at the time points 30 -
days, 6 months and 12 months after the angiography. 298
patients returned the questionnaire.
The MacNew is a disease specific instrument for pa-
tients with cardiac disease describing with 3 scales the
physical, emotional and social quality of life. In addition
a global quality of life value can be calculated. Each scale
ranges from 1 to 7 with 1 indicating a poor and 7 a per-
fect quality of life. The instrument is not yet validated
for the calculation of QALY’s.
The purpose of our repeated measurements with this
instrument was to determine how fast patients return to
a stabilized health status after primary PCI.
Reimbursement comparison
In order to identify the impact of the network structure
implementation on reimbursement subsequent years had
to be compared. Accordingly the impact of other struc-
tural and price changes between years had to be elimi-
nated. In this respect the change of the reimbursement
system from the German Fallpauschalensystem (lump
compensation system) to the G-DRG (German Diagnosis
Related Groups) system after 2002 was a major challenge.
Birkemeyer et al. Health Economics Review 2013, 3:10 Page 3 of 8
http://www.healtheconomicsreview.com/content/3/1/10Standardization of reimbursement by a relative
weight model
There was no established methodology for comparison
of health expenditures before and after transition from
the German Fallpauschalen to the G-DRG system. Use
of the 2005 G-DRG grouper for the entire patient cohort
seemed to be an appealing concept to stratify patients
according to severity of disease manifestation, extent of
required medical procedures and co morbidities follow-
ing identical rules. An increase of the mean relative
weight from 2002 to 2005 respectively 2008 in patient
cohorts with comparable baseline characteristics should
be an appropriate indicator for the change in medical
care driven by the network organization. Furthermore
this could be easily translated into comparable mean re-
imbursement for patient treatment in different years. It
was however soon evident that the available data docu-
mentation of the 2002 patients was not suitable for
standard grouping.
Therefore a simplified stratification system was created
based on the clinical and procedural information available
for each patient leading into one of six reimbursement
groups comparable to the main G-DRG’s for STEMI pa-
tients in 2005. The algorithm used checked for the du-
ration of intensive care stay (decision criteria: > 5 days),
presence of cardiogenic shock, initial resuscitation, use of
an intra aortic counterpulsation (IABP), performance of
PCI, amount of stents implanted, interhospital transfer
and transfer for coronary artery bypass grafting (CABG).
If patients got more than one stent implanted they were
stratified into the “complex PCI” group, if patients stayed
more than five days on intensive care and/or had a cardio-
genic shock and/or an initial resuscitation an/or an IABP
implanted they were considered as receiving “complex
care”. Assumed relative weights for each reimbursement
group were derived from the 2005 STEMI G-DRG’s. For
patients with inter hospital transfer (hub and spoke) two
separate relative weights for the interventional and the
peripheral stay were determined (with a 40% discount on
the interventional and a 30% discount on the peripheral
relative weight to compensate for reimbursement cuts due
to short stays). For performance of CABG an assumed
relative weight of 5.5 was added (also derived from the
2005 G-DRG catalogue). Use of drug eluting stents was
not included in the relative weight model.
All 536 registry patients of different years were strati-
fied in one of the reimbursement groups according to
the described algorithm. Further stratification was done
according to inter hospital transfer (hub and spoke) and
transfer for CABG. One patient in the “Angiography
only” group had an excessively high reimbursement
compared to the mean of the group and was excluded
from further analysis. The mean relative weight for a
STEMI patient treated in the years 2002, 2005 and 2008was determined. Afterwards the mean relative weight
was multiplied with the real base rate (€2855) valid
for the network area in 2005 leading to a standardized
mean reimbursement received for a STEMI patient in
the network area in the respective years. After further
standardization to a hypothetical patient number of 180
patients overall reimbursements per year could be com-
pared. Cost deltas were calculated.
Transportation and other costs
Transportation costs were not included in the final ana-
lysis, as they are highly variable within Germany and reim-
bursement rules vary a lot between countries. Actually
numbers of overall and reimbursed EMS transfers de-
creased with network implementation.
Before the network about 70% of patients from the
catchment area of the non-invasive hospitals had an
EMS-escorted transfer to the peripheral hospital and
one third an early EMS-escorted transfer from the per-
ipheral hospital to primary PCI. In addition some per-
ipheral patients were transferred late during their
hospital stay for coronary angiography and also some
transferred back. With the network implementation the
number of initial EMS transfers to the peripheral hos-
pital markedly decreased whereas the number of direct
transfers to the invasive facility from the catchment area
of the non-invasive hospitals increased as did the num-
ber of back transfers to the peripheral hospitals.
In the German reimbursement system each local EMS
has a standard fee for an ambulance transfer independ-
ent of distance which only differs according to the fact
that an emergency physician is aboard or not; costs for
airbound transport can differ but this option was rarely
used; back transfers to lower level hospitals are in gen-
eral not reimbursed at all and are therefore organized
and paid by the invasive facility. The uncorrected num-
ber of reimbursed EMS escorted transfers dropped from
2002 to 2005 by 47 respectively from 2002 to 2008 by 31.
The average costs for an EMS-escorted transfer at that
time were about €400 in the network area leading to an
uncorrected overall cost decrease of about €19.000 respect-
ively €12.000 in 2005 and 2008. If back transfers would
have been reimbursed the major part of the cost saving
would have disappeared, even more after standardization
for patients numbers.
Networks have no direct reimbursement effects in the
German system. Costs for necessary organisational
changes and running of the network were anyway negli-
gible. All meetings were organized by the representatives
of the different organisations during their working hours
within the hospital facilities. The biggest part of commu-
nication was done electronically. No dedicated staff was
hired for the project. The existing technical equipment
fulfilled the needs.
Table 1 Baseline clinical characteristics of acute regional









Age (yrs.) 67 ± 13 66 ± 13 63 ± 14 n.s.
Female gender 41% 29% 27% 0.01
Diabetes 29% 24% 26% n.s.
Current smoker 33% 39% 35% n.s.
Arterial hypertension 69% 61% 68% n.s.
Hyperlipidemia 63% 45% 46% <0.01
Previous myocardial
infarction
12% 9% 10% n.s.
Previous PCI 4% 7% 6% n.s.
Previous CABG 1% 2% 2% n.s.
Cardiogenic shock 11% 13% 15% n.s.
Post CPR 6% 9% 12% n.s.
Data are presented as mean value ± SD or percentage of patients.
CABG, Coronary bypass graft; CPR, Cardiopulmonary resuscitation; n.s, Non
significant; PCI, Percutaneous coronary intervention.
Table 2 Treatment strategies and outcome in acute











21% 9% 10% <0.01
Fibrinolysis 27% 2% 1% 0.01
Primary PCI 53% 89% 89% <0.01
Hospital mortality 16% 9% 7% 0.01
6-month mortality 19% 10% 10% 0,01
No immediate revascularisation also includes intended but aborted
primary PCI’s.
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discharge period was not possible because of lack of ac-
cess to ambulatory data. Decision was made to renounce
on further modelling.
Source of change analysis
For crosscheck of the relative weight model a top down
source of change analysis was performed including the
following steps: summation of real per patient reim-
bursement stratified according to year and reimburse-
ment group; inclusion of CABG; standardization to 180
patients per year, standardization of reimbursement
2002 and 2008 to the 2005 level, calculation of base
rates (division of the standardized overall reimbursement
per year by the mean relative weight) with correction for
drug eluting stent use (extra reimbursement).
Cost effectiveness analysis
After calculation of the reimbursement changes attribut-
able to the network implementation a cost effectiveness
analysis was performed. The primary endpoint considered
was mean costs per saved life with the 95%-confidence in-
tervals computed using nonparametric bootstrapping.
Statistical methods
Data were analyzed according to established standards
of descriptive statistics. Categorical variables were com-
pared by a maximum likelihood χ2 test. Continuous va-
riables are reported as medians with interquartile range or
mean ± SD. For comparisons, the t test (based on testing
for normal distribution) or the 2-tailed Mann–Whitney U
test was used as appropriate. Odds ratios and 95% confi-
dence intervals were provided where appropriate. A
p-value of less than 0.05 was considered significant. Boot-
strapping was done with 5000 case resamplings.
Results
Five hundred and thirty six consecutive patients (n = 536)
with the diagnosis of acute STEMI (<12 h) were included
in this area-wide registry irrespective of their treatment:
185 patients in 2002 (last year before the myocardial in-
farction network was established), 163 patients in 2005
(first year of complete network implementation) and 186
patients in 2008 (“chronic” network structures).
Patients’ baseline characteristics were quite compar-
able between different years (Table 1). There was how-
ever a significantly higher proportion of females in 2002
and a trend over time to more patients being admitted
in shock and after resuscitation.
Implementation of the network structures led to differ-
ent utilization of reperfusion and reperfusion methods. In
2002 27% of patients received fibrinolysis and 53% pri-
mary PCI while 21% of patients received no early reperfu-
sion treatment at all (including the 3% of patients withaborted PCI). In 2005 this had changed to 2% fibrinolysis,
89% primary PCI and 9% without reperfusion treatment.
These results have been previously published [18]. In our
present analysis the network effect was confirmed in 2008
with 1% fibrinolysis, 89% primary PCI and 10% without
reperfusion treatment.
Regional mortality for STEMI differed considerably
between 2002 and 2005: at hospital discharge the differ-
ence was 7% (16% versus 9%), which increased to 9%
(19% versus 10%) after 6 month. This was mainly driven
by a mortality reduction in the elderly and shock pa-
tients [17]. The mortality effect was confirmed in 2008
with a hospital mortality of 7% and a 6 month mortality
of 10% (Table 2).
Repeated measurements with the MacNew quality of
life questionnaire showed that STEMI patients regained
a stable health status within 30 days after primary PCI
which then basically remained unchanged up to
Table 3 Subjective disease related quality of life (QoL) in 298 patients at different time points after primary PCI













Global QoL 5.1 ± 1.1 5.2±1.2 5.3±1.1 .318 .312 .072
Physical QoL 5.1±1.2 5.2±1.3 5.3±1.2 .473 .170 .111
Emotional QoL 5.1±1.2 5.1±1.2 5.2±1.1 .391 .854 .248
Social QoL 5.2±1.2 5.4±1.3 5.4±1.2 .063 .357 .014
Scales range from 1 to 7 with 1 representing poor and 7 perfect health.
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trend for deterioration between 30 days and 6 months
from which they recovered up to 12 months.
Table 4 displays the results of the patient stratification
into the relative weight model. Most striking is the jump
in the number of patients requiring complex care from
2002 to 2005 in the PCI centre. This represents a change
in the pattern of care for shock and post resuscitation
patients from a medical stabilization attempt in the
nearest hospital to an early transfer for immediateTable 4 Patient stratification into the relative weight model
Reimbursement stratum CABG Ye
Hub only 20
A: Complex care 9
B: Complex PCI 25
C: Non-complex PCI 37
D: Angiography. only 8
E: No angiography 1
80
Transfer A: Complex care CABG 3
Cons. 5
B: Complex PCI CABG 4
Cons. 5
C: Non-complex PCI CABG 1
Cons. 27
D: Angiography only CABG 3
Cons. 8
E: No angiography Cons. 4
60
Spoke only X: External CABG 1
Cons. 33
PCI (not in hub) 11
45
18
Mean relative weight 2.135 2.
Change 0.951 1mechanical revascularisation. In addition more patients
received complex PCI with less patients being transferred
for CABG. An increase of approximately 10% of the mean
relative weight respectively mean reimbursement for a
network area STEMI patient from 2002 to 2008 seems to
be attributable to network effects.
The comparison of the mean reimbursement for a
STEMI patient in 2005 derived from the model (mean
relative weight multiplied with the real base rate 2005)
with the real reimbursement served as a quality indicatorRelative weight hub Relative weight spoke
ar






114 135 0.6 0.7
1 2 1.985 3.85
2 2 1.985 0.805
3 3 1.269 3.85
21 22 1.269 0.805
1,246 3.85
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bursement (without DES) in 2005 was €6412, the mean
real reimbursement was €6055 (plus €578 for DES).
As first step of the source of change analysis real per
patient reimbursement data plus estimated CABG costs
per year were summed up. Then the real cost sums of
2002 and 2008 were standardized to the 2005 reimburse-
ment level. Third step was standardisation to a hypothet-
ical patient number of 180 patients per year. Afterwards
mean reimbursement was calculated for each different
year. After correction for different DES use (extra reim-
bursement) the cost delta between 2002 and 2008 was
matching the result of the relative weight model. As a
quality indicator for the top down source of change ana-
lysis a virtual base rate was calculated (mean standardized
reimbursement divided by mean modelled relative weight
2005) and compared to the real base rate 2005. The virtual
base rate (after correction for DES use) was €2534, the
real base rate €2855.
The 10% increase in reimbursement for the index hos-
pital stay and the observed mean 8% decrease in mortal-
ity at discharge after network implementation translated
into short term mean costs per saved life of €7727 (ref-
erence: 2005 German reimbursement level). A 95%-con-
fidence interval of €-3.500 to 36.700 was computed
using non parametric bootstrapping (Figure 1).
Discussion
Implementation of a myocardial infarction network in
a rural German surrounding aiming at identical treat-
ment of all consecutive STEMI patients with transfer to
primary PCI increased mean health care expendituresFigure 1 Distribution of incremental costs per saved life during
index stay (reference: 2005 reimbursement) for an emergency
medical services-based strategy of transporting every patient to
primary PCI; result of a bootstrap analysis with 5000 re-samplings.for the index hospital stay by approximately 10%. In-
creased expenditures were mainly driven by the higher
number of patients receiving complex intensive care
after STEMI complicated by cardiac arrest and/or shock.
In addition a higher number of complex PCI procedures
was performed which was paralleled by a decrease in the
number of patients with early post myocardial infarction
CABG. Transportation costs were not considered in
this analysis as they are highly variable even within the
German reimbursement system. If considered they
would have attenuated the network effect on local
health care expenditures by 1-2%.
The population based registry showed an absolute de-
crease of STEMI mortality after network implementation
of mean 8% at hospital discharge and 9% at 6 month.
The increase of the mortality benefit over time fits with
the long term follow up of a randomized trial comparing
primary PCI with fibrinolysis where the mortality differ-
ence of 6% after 30 days increased to 11% after a mean
follow up of 5 years [23].
Before network implementation reperfusion therapy
was performed at the discretion of the nearest emer-
gency department with concomitant use of transfer PCI
and fibrinolysis. The observed regional mortality of 16%
at that time matches well the data from the population
based WHO MONICA (monitoring trends and determi-
nants in cardiovascular disease) and its successor project
KORA (Kooperative Gesundheitsforschung in der Re-
gion Augsburg) [24,25], which found an overall hospital
infarction mortality of approximately 17% in the years
2001 to 2003. On the other hand the decrease of hos-
pital mortality to mean 8% after implementation of the
network fits well with observations from other network
registries in Austria, Czech and Italy [12,16,17].
Our findings translate into incremental costs of €7727
per saved life during index hospital stay (95% CI €-3.500
to €36.700) attributable to the myocardial infarction net-
work (referenced to 2005 German reimbursement).
For comparability reasons the magnitude of gained
quality adjusted life years (QALY) due to the network
implementation can be estimated. The 6 month mortal-
ity reduction already leads to an approximate gain of 8
unadjusted life years in a cohort of 180 patients during
this short time span. It is known that the self reported
quality of life in patients having stabilized after acute
coronary syndromes is comparable to patients with
stable coronary artery disease that never experienced a
myocardial infarction [26,27]. The health utility score
(EQ-5D index, US) in a large cohort of coronary heart
disease patients with stable health status was reported to
be approximately 0.7 [27] which seems to correspond
well to the quality of life reflected by the indices we have
measured with the MacNew instrument already in the
early post interventional time course [26]. Taking this
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reduction could account for as much as 5.6 QALY’s.
Furthermore the general replacement of fibrinolysis by
primary PCI leads to a lower number of reinfarctions
and strokes translating into an additional positive effect
on QALY’s gained [22]. Even though we have no data
on health care expenditures after hospital discharge in
our study cohort it seems reasonable to assume that
the cost delta does not continue to increase with more
expected therapy associated complications after fibrin-
olysis compared to documented early stabilization of
health status in the primary PCI group. Considering
only the early gain this would translate into costs of
about 20.000 €/QALY.
Obviously this number is very speculative and com-
parability of this finding with the results of an American
cost simulation estimating the costs per QALY for
establishing an emergency medical services-based strat-
egy of routine transfer PCI therefore limited. The ob-
served magnitude in our registry seems to be higher
than the estimated $506 (95% CI $474 to $519) in the
simulation [22]. However under the assumption of a
persisting mortality benefit in an acceptable health
status over five years the simulated results seem to be
reasonable.
Furthermore it seems reasonable to assume that the
incremental cost effectiveness ratio of our network or-
ganisation is well below the often cited willingness-to-
pay threshold of €80.000/QALY; and also below the
estimated incremental cost effectiveness ratio of approxi-
mately €44.000 Euro/QALY of primary prophylactic ICD
therapy in patients with a left ventricular ejection fraction
< 40% [28].Limitations
This study suffers the inherent problems of any observa-
tional study. However, we included all consecutive pa-
tients admitted with the same diagnosis in the same
territorial area and hospitals in three subsequent time
frames. So we got a comprehensive view on the effect of
the modification of our regional treatment concepts on
the outcome of our infarction population.
Lack of ambulatory cost data definitely is a major limita-
tion; in addition primary PCI patients were followed with
a disease specific quality of life questionnaire (German
version of the MacNew) which is not validated for calcula-
tion of QALY’s.
Further limitations are the retrospective identification
of the subset of patients treated conservatively in the
non-invasive hospitals, the sample size which limits the
power of any analysis and the assumptions that had to
be made for cost comparison between different years
and reimbursement systems.Conclusions
Our data confirm that the short term cost effectiveness
of a German myocardial infarction network organisation
aiming for primary PCI in all STEMI patients is within
well accepted boundaries.
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